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The complete 5* sequence of the Epstein-Barr virus 3.5-kb latent membrane protein 1 (LMP1) mRNA,
expressed in nasopharyngeal carcinoma, has been determined. The transcript initiates from heterogeneous
start sites within the first terminal repeat (TR) of the viral genome. This region is TATA-less, consistent with
heterogeneous starting, but contains multiple GC-rich elements which potentially interact with the Sp1
transcription factor. Expression of the 3.5-kb mRNA was consistently detected in nasopharyngeal carcinoma
samples and in additional cell types, including a Burkitt’s lymphoma. This is the first identification of an
Epstein-Barr virus mRNA containing TR sequence and the first report of the ability of the TR to function as
a transcriptional promoter.
LMP1 is essential for the Epstein-Barr virus (EBV)-induced
growth transformation of normal B cells to immortalized lym-
phoblastoid cell lines (LCLs) in vitro and is likely to be an
important component of the EBV-associated epithelial cell
malignancy nasopharyngeal carcinoma (NPC) (22). In LCLs,
LMP1 is predominantly encoded by a 2.8-kb mRNA which
initiates from a site (ED-L1) within the BamHI N-EcoRI D
fragment of the EBV genome (13, 19). Expression from ED-L1
in LCLs requires transactivation by the EBNA2 protein, which
interacts with cellular transcription factors, including J kappa
and PU.1 (1, 16, 20, 24, 33). Transcription of LMP1 has been
detected in most samples of NPC, and this expression occurs in
the absence of detectable EBNA2 (12, 27, 34). In C15, a nude
mouse-passaged NPC, two 39 coterminal LMP1 transcripts of
2.8 and 3.5 kb have been detected at equal levels by Northern
(RNA) blotting. A partial cDNA, c103, derived from the larger
transcript has been previously isolated from C15, but the com-
plete 59 sequences and the start site of the 3.5-kb mRNA have
not been identified (15). The expression of the 3.5-kb mRNA
in different tissues also has not been well characterized. In this
study, the 59 sequence and initiation region of the 3.5-kb LMP1
mRNA were identified by Northern blotting, RNase protection
assays, and cDNA cloning. In addition, the start site of the
2.8-kb LMP1 mRNA in NPC was mapped. The expression of
the 3.5-kb mRNA was assayed in several EBV-infected cell
types, and the relative levels of the 2.8- and 3.5-kb mRNAs
were determined for NPC and lymphoid samples.
The 59 sequences of the 3.5-kb LMP1 mRNA were deter-
mined by Northern blotting using RNA from C15 and an
EBV-infected LCL, B95-8, with single-stranded, [32P]UTP-la-
beled RNA probes as shown in Fig. 1A. Northern blot hybrid-
ization with probe A, which overlaps the ED-L1 start site,
detected the 2.8- and 3.5-kb mRNAs in C15 at approximately
equal levels (Fig. 1B). A much higher relative level of the
2.8-kb mRNA was detected in B95-8 than in C15, and the
3.5-kb mRNA was detected in B95-8 only upon long exposure
(Fig. 1B). These results are in agreement with previous find-
ings which indicate that the larger transcript is preferentially
expressed in NPC samples compared with LCLs (15). Hybrid-
ization with probe B, which contains sequences immediately 59
to the c103 cDNA and extends 48 nucleotides (nt) into the first
terminal repeat (TR) element (Fig. 1A), also detected the
3.5-kb mRNA in C15 and, at a low level, in B95-8 (Fig. 1B).
Hybridization performed with an additional probe, probe C,
which is located completely within the first TR (Fig. 1A), did
not detect the 3.5-kb mRNA in any sample even on long
exposure (Fig. 1B). These results indicated that the 3.5-kb
LMP1 mRNA contains sequences immediately adjacent to the
TR and possibly includes sequences in the proximal region of
the first TR element.
In order to determine if the region of the 3.5-kb mRNA
which hybridized to probe B is unspliced, this probe was gel
purified and used in an RNase protection assay (29). In C15, a
340-nt band representing partial protection of the 359-nt probe
was abundant, and a lower level of fully protected probe was
also detected (Fig. 1C). In B95-8, the fully protected probe was
detected predominantly, and partially protected bands of 340
nt and 320 nt were detected at lower levels (Fig. 1C). The
detection of both fully and partially protected probe in this
assay was not consistent with splicing of the transcript in this
region or with the existence of additional 59 exons. These data
indicated that probe B overlaps a proximal transcription start
site at approximately bp 170112 (30 nt within the first TR) and
that an additional start site(s) is located 59 to the probe se-
quences. In C15, the majority of the transcripts started at the
proximal site, while in B95-8, initiation further 59 was more
prevalent (Fig. 1C).
Additional RNase protection assays were performed with
C15 RNA and single-stranded RNA probes which contain
sequences overlapping the 59 end of probe B (Fig. 1A). Hy-
bridization of C15 RNA with probe D resulted in the detection
of multiple partially protected bands of 285 to 300 nt (Fig. 1D).
The most abundant band, of 290 nt, corresponded to a start
site at bp 170000, in close agreement with the major start site
identified in C15 by using probe B. The additional partially
protected bands detected by using probe D indicated the pres-
ence of multiple transcription start sites within this region.
Hybridization of C15 RNA with probe E (Fig. 1A) resulted in
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the detection of a major partially protected band of 79 nt and
multiple weakly detectable larger bands of up to 112 nt (data
not shown). The 79-nt band correlated to a start site at bp
170114, in close agreement with the results of the previous
assays, while the larger bands again indicated additional 59
start sites.
To specifically identify the sites of transcription initiation of
the 3.5-kb mRNA, 59-end cDNA cloning was performed by
using the 59 rapid amplification of cDNA ends (59RACE) assay
(Fig. 2A) (14). C15 poly(A) RNA was reverse transcribed, and
an equivalent aliquot of RNA to which no reverse transcriptase
(RT) was added (RT-negative control) was processed in par-
allel. Oligo(dT)-primed C15 cDNA was treated with terminal
deoxynucleotidyl transferase (Boehringer Mannheim) in the
presence of dATP and then subjected to amplification with an
oligo(dT) primer and a gene-specific primer (169810-R; bp
169810 to 169829, 59-GGGAAGCGGCAGTGTAATCT) and
nested amplification with primer 170035-R (59-AAAAGGGT
GTGGGCTGTGCG) (Fig. 2A). To ensure that the amplified
material was derived from RNA and not from contaminating
DNA, the nested PCR material was analyzed by Southern
blotting with an internal oligonucleotide probe (170060-R; 59-
CATGAGGCAGGCGCGGA) (28). Hybridization with am-
plified products of 100 to 150 bp was detected in the C15
cDNA sample but not in the RT-negative control (data not
shown). The amplified 59RACE cDNA was cloned, and se-
quence analysis of 23 cDNA clones identified eight distinct
cDNA 59 ends which were clustered in three regions (Fig. 2B).
This result was consistent with the identification of heteroge-
neous start sites by the RNase protection assays. The 16
59RACE cDNA clones terminating between bp 170113 and
170125 contained four distinct 59 ends whose locations were
also in close agreement with the major start site in C15 iden-
tified by the RNase protection assays. It is possible that some
or all of the clones which terminated between bp 170121 and
170125 resulted from inadvertent annealing during the PCR
amplification of the oligo(dT) primer to the poly(dA) tract in
the genomic sequence at this site. A second, more distal cluster
of 59 ends, consisting of four cDNA clones terminating at three
distinct sites, was located between bp 170173 and 170184. A
third site of cDNA 59 ends, at bp 170075, may also have
resulted from annealing of the oligo(dT) primer to the
poly(dA) tract at this site in the genomic sequence.
cDNA cloning was also performed by using inverse PCR
(26). C15 poly(A) RNA was primed with gene-specific primer
FIG. 1. The 3.5-kb LMP1 mRNA is unspliced 59 of ED-L1 and contains
proximal TR sequence. (A) The coordinates according to the B95-8 sequence of
the rightward, single-stranded RNA probes used for Northern blotting and
RNase protection assays are depicted relative to the 2.8-kb LMP1 mRNA and
ED-L1 start site (bent arrow), the LMP1 open reading frame (shaded), the c103
cDNA, and the first terminal repeat element (2). Probe A, derived from an
AccI-MluI subclone of c103, contains sequences overlapping the ED-L1 start site
and therefore hybridizes with both the 2.8- and 3.5-kb LMP1 mRNAs. Probes B
to E were derived from plasmids generated by PCR of C15 DNA. (B) Northern
blot hybridizations were performed with identical panels of C15, B95-8 (B95),
and Louckes (LKE; EBV negative) poly(A) RNA (30 mg) and with RNA probes
A, B, and C as previously described (28). The 2.8- and 3.5-kb LMP1 mRNAs are
indicated. A 3-day exposure is shown for probe A; a 7-day exposure is shown for
probes B and C. (C) T2 RNase protection assay of C15, B95-8, and Louckes
poly(A) RNA (30 mg) with gel-purified probe B. Hybridization was performed at
508C and was followed by digestion at 308C and electrophoresis on an 8%
polyacrylamide–formamide gel. Fragment sizes were determined by comparison
with RNA and DNA molecular weight standards. The 340-nt protected fragment
corresponds to sequence extending to bp 170112, within the first TR. FP, fully
protected probe; PP, partially protected probe. (D) A T2 RNase protection assay
of C15 and Louckes poly(A) RNA (30 mg) with gel-purified probe D was
performed as described above. The major partially protected band of 290 nt in
C15 corresponds to an initiation site at bp 170100.
FIG. 2. Identification of 59 ends by cDNA cloning. (A) The 59RACE assay
was performed by reverse transcription of 2 mg of DNase-treated oligo(dT)-
primed C15 poly(A) RNA, followed by treatment with terminal deoxynucleotidyl
transferase in the presence of dATP and two rounds of PCR. PCR primers
(arrowheads) are 18- to 24-mers numbered at their 59 ends according to the
B95-8 sequence and extend in the direction indicated (R, rightward) relative to
the standard EBV genome (2). (B) cDNA 59 ends of 23 LMP1 59RACE cDNAs
and 1 inverse PCR cDNA isolated from C15 mRNA are depicted by bent arrows
at the indicated coordinates. The number of isolated cDNAs terminating at each
position is also indicated. The exact 59 ends of cDNAs terminating between bp
170075 and 170077 and between bp 170121 and 170125 could not be determined
because of stretches of poly(dA) in the genomic sequence at these sites.
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169420-R (59-GTCCTCGAGGGGGCCGTCGCG) and re-
verse transcribed by using Superscript II (Life Technologies).
Following second-strand synthesis, the cDNA was treated with
T4 DNA ligase (Promega) to form concatemerized molecules
which could then be amplified by PCR using primers 169700-R
(59-GTGTTATAAAAGCGGGTCCC) and 169679-L (59-CC
CTTTCTACGCTTACATGC). Sequencing of a single inverse
PCR clone indicated a start site at bp 170173, coinciding with
the location of the distal cluster of start sites identified by the
59RACE cDNA clones (Fig. 2B).
These assays have identified transcription start sites in C15
that are clustered in a proximal, major region and a distal,
minor region separated by approximately 60 bp. This configu-
ration is similar to that of the well-conserved mammalian di-
hydrofolate reductase genes, which are TATA-less and contain
proximal, major and distal, minor start sites that are separated
by approximately 45 bp (4). The major start site region is
located within 20 bp of the start of the TR sequences. Initiation
of transcription was detected only from within the first TR
element and not from within distal TR elements, suggesting
that unique sequences adjacent to the first TR may contribute
to promoter activity.
The promoter region 59 of the 3.5-kb mRNA start sites does
not contain TATA or CAAT box sequence elements. This
observation suggested that the regulatory elements of this pro-
moter may include GC-rich elements (GC boxes), which have
been shown for other TATA-less promoters to regulate tran-
scription by binding of the Sp1 transcription factor (11). The
TR sequences are highly GC-rich and contain numerous ele-
ments which have a high degree of homology to known Sp1-
binding sites (5, 21). In the TR sequence of C15, a 29-bp region
containing 8 overlapping elements with 70% homology to the
Sp1 consensus sequence, 59-GGGGCGGGGC, is centered ap-
proximately 42 bp 59 of the major start site region (GC-I [Fig.
3A]). A 17-bp region containing two overlapping elements with
70% homology to the Sp1 consensus sequence is centered
approximately 50 bp 59 of the minor start site region (GC-II
[Fig. 3A]). To address the possibility that these elements in-
teract with Sp1, TR sequences were inserted 59 of the chlor-
amphenicol acetyltransferase (CAT) gene to generate the re-
porter gene constructs TR313-CAT (bp 170077 to 170313) and
TR560-CAT (bp 170077 to 170560). These constructs were
transfected into Drosophila melanogaster SL2 cells, which lack
endogenous Sp1 activity, with or without an exogenous Sp1-
expressing construct (10). A construct containing a frameshift
mutation in the Sp1 gene was used in parallel cotransfections
as a control (35). Transactivation of TR-CAT constructs in the
presence of Sp1 as determined by CAT assay was compared
with that of the promoterless parent construct (pBS-CAT) and
that of a simian virus 40 early promoter construct (SV40E-
CAT) which contains six consensus Sp1-binding sites (11). Ex-
periments were performed in triplicate, and transactivation
was measured as the percent acetylation of [14C]chlorampheni-
col in the presence of Sp1 divided by the percent acetylation in
the presence of the frameshift mutant (29). By this method,
transactivation of TR313-CAT increased by an average of six-
fold in the presence of Sp1, which represented a significant
increase over the threefold transactivation of the negative con-
trol construct, pBS-CAT. Transactivation of TR560-CAT in-
creased by an average of 17-fold in the presence of Sp1 (Fig.
3B).
These results indicated that the TR sequences contain prox-
imal Sp1-responsive elements within the region from bp
170077 to 170313 and additional, distal Sp1-responsive ele-
ments within the region from bp 170313 to 170560. In EBV in
vivo, the reiteration of Sp1-responsive elements in adjacent TR
elements could augment transactivation of the 3.5-kb mRNA
(9, 25). Interestingly, the promoter region 59 of the start site
(ED-L1) for the 2.8-kb LMP1 mRNA contains a single Sp1-
binding site (CCGCCC) located at position 232, and four
additional potential Sp1-binding elements are located between
positions 2362 and 2482. This raises the possibility that in
epithelial cells Sp1 could contribute to the expression of both
the 2.8- and 3.5-kb LMP1 mRNAs.
The expression of the 3.5-kb LMP1 transcript in additional
NPC samples, tissue types, and cell lines was determined by a
reverse transcription-based PCR assay (28). Oligo(dT)-primed
cDNA was amplified by using a PCR primer located 59 of the
ED-L1 start site in conjunction with a primer located within
LMP1 exon 3. cDNAs starting at ED-L1 are not amplified in
this assay, and cDNAs starting 59 of ED-L1 can be distin-
guished from DNA by the exclusion of 154 bp of intron se-
quences (Fig. 4A). PCR amplification using primers 168888-R
(59-GGAAGAAGGCCAAAAGCTGCC) and 169550-L (59-
GCCCTACATAAGCCTCTCAC) resulted in a genomic prod-
uct of 663 bp and a spliced product of 509 bp, representative of
the 3.5-kb mRNA, that were detected by hybridization with an
oligonucleotide probe within exon 1 (Fig. 4A, probe 1). The
509-bp spliced product was detected in C15 and in three ad-
ditional passaged tumors (C17, C18, and C19), in three NPC
biopsy samples (N1, N10, and N13), and in the LCL IB4 (Fig.
4B) (6, 7). The identity of the spliced product was confirmed by
hybridization with an oligonucleotide probe within the first
FIG. 3. TR promoter analysis. (A) CAT reporter gene assays were per-
formed with constructs containing EBV sequences from bp 170313 to 170077
(TR313-CAT) and from bp 170560 to 170077 (TR560-CAT) as depicted. The
locations of the major start region (large bent arrow), the minor start region
(small bent arrow), and potential Sp1-binding elements (GC-I and GC-II; see
text) within each construct are shown. (B) CAT assay results for Drosophila SL2
cells transiently transfected with 5 mg of pBS-CAT (negative control), TR313-
CAT, TR560-CAT, or SV40E-CAT (positive control) and 5 mg of an Sp1-
expressing construct (1) or an Sp1 frameshift mutant (2) are depicted as
average percents acetylation (Avg. %Ac.) of triplicate samples. The range of
values for triplicate samples is indicated with brackets. The fold increase in
percent acetylation is calculated by the following formula: Avg. %Ac. with
Sp1/Avg. %Ac. with frameshift mutant.
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intron of the LMP1 transcript (Fig. 4A, probe 2). This probe
hybridized only to the unspliced 663-bp genomic product in
these samples and not to the 509-bp spliced product (data not
shown).
The 3.5-kb LMP1 mRNA was also detected by reverse tran-
scription-based PCR in additional samples by using nested sets
of PCR primers. Oligo(dT)-primed cDNA was first amplified
by using primers 168813-R (59-CAACCAATAGAGTCCAC
CAGT) and 169747-L (59-CCACCGCATTCCCACAGCTT)
and then subjected to nested amplification using primers
168888-R and 169550-L. The nested PCR amplification re-
sulted in the detection of the 509-bp spliced product in four
additional NPC biopsy samples, in a Burkitt’s lymphoma (BL)
biopsied at two sites (liver and kidney), in a parotid carcinoma,
and in two EBV-positive T-cell lymphomas (Fig. 4C and data
not shown) (8). By using nested PCR, the 3.5-kb LMP1 mRNA
was also detected in the Akata and Mutu BL cell lines (data
not shown). The identity of the spliced product in each sample
was again confirmed by hybridization with an oligonucleotide
probe within the first intron of the LMP1 transcript (Fig. 4A,
probe 2; data not shown). Importantly, the data demonstrate
that the 3.5-kb LMP1 transcript is expressed in additional
examples of EBV-infected cells in vivo, including T-cell lym-
phoma and BL, which lack expression of EBNA2.
The relative levels of expression of the 2.8- and 3.5-kb LMP1
mRNAs in EBV-infected cell lines and tissue samples were
determined by an RNase protection assay using an RNA probe
which overlaps the 2.8-kb mRNA start site (Fig. 1A, probe A).
Use of this probe provided an approximate determination of
the relative abundance of each transcript in these samples. By
this assay the 3.5-kb mRNA was detected as a fully protected
band of 346 nt in C15 and in a pool of NPC biopsy samples, in
the LCL IB4, and in the BL cell line Akata, confirming the
results obtained by reverse transcription-based PCR (Fig. 4D).
The relative levels of the LMP1 transcripts in C15, the NPC
biopsy pool, and the IB4 and Akata cell samples were quanti-
fied by densitometry of the RNase protection autoradiogram.
All bands of approximately 280 to 295 nt in these samples were
included in the estimation of the 2.8-kb mRNA, as these bands
represent the multiple start sites that have been identified for
this transcript in LCLs (13, 19). In C15 and the NPC biopsy
pool, the 3.5- and 2.8-kb mRNAs were present in approxi-
mately equal abundances. In IB4, the 2.8-kb mRNA was ap-
proximately 9-fold more abundant than the larger transcript,
while in Akata the 2.8-kb mRNA was at least 10-fold more
abundant (data not shown). Therefore, although the 3.5-kb
LMP1 transcript is consistently expressed in lymphoid cells in
vitro, the relative level of expression is significantly higher in
NPC samples. In C15, the 2.8-kb mRNA was detected as mul-
tiple partially protected bands of 280 to 305 nt with a major
partially protected band of 295 nt, indicating initiation at or
near bp 169515, coincident with the start site that has been
identified for this transcript in LCLs (Fig. 4D). The additional
minor bands indicate the existence of multiple, clustered start
sites for the 2.8-kb mRNA in C15, as has also been reported
for this transcript in LCLs (13, 19).
LMP1 is essential for the transformation of normal B cells in
vitro and is sufficient to transform established rodent fibroblast
cell lines to reduced serum dependency, growth in soft agar,
FIG. 4. Expression of the 3.5-kb LMP1 mRNA in vivo. (A) PCR was per-
formed with oligo(dT)-primed cDNA by using PCR primers numbered as in Fig.
2 and positioned as shown relative to the LMP1 mRNAs and start sites (bent
arrows) and open reading frame (shaded). Oligonucleotide probe 1, located
within LMP1 exon I, hybridizes with both spliced and genomic PCR products.
Probe 2 (169130-R), located within the first intron, hybridizes only with un-
spliced, genome-sized products. Probe 1, 169305-L (59-CCTTTGCTCTCAT
GCTTATAA); probe 2, 169130-R (59-TGGGGAAAGAGGAGAAAGTG). (B)
PCR amplification (40 cycles) using primers 168888-R and 169550-L resulted in
a spliced product of 509 bp (S) and a genomic product of 663 bp (G), which were
detected by Southern blot hybridization with probe 1. Spliced products were
detected only in cDNA samples (RT1) and not in RT-negative controls. C15,
C17, C18, and C19 are nude-mouse-passaged NPC tumors; N1, N10, N11, N12,
and N13 are NPC biopsy samples; and IB4 is an LCL. The spliced products
detected in C15, C17, C18, C19, N1, N10, N13, and IB4 did not hybridize with
probe 2. N11 and N12 were positive for the spliced product upon nested ampli-
fication (data not shown). (C) Nested PCR was performed with primers
168813-R and 168747-L (40 cycles) and was followed by amplification using
primers 168888-R and 169550-L (15 cycles). Unspliced, genomic products of 663
bp (G) and spliced products of 509 bp (S) were detected by Southern blot
hybridization with probe 1. N59 and NKP are NPC biopsy samples. BL,L and
BL,K are from a single BL patient biopsied at two sites, liver and kidney,
respectively. TL441 is an EBV-positive T-cell lymphoma. D, B95-8 DNA. The
spliced products detected in N59, the BL biopsy samples, and TL441 did not
hybridize with probe 2. Spliced product was detected in NKP upon 30 cycles of
nested amplification (data not shown). (D) A T2 RNase protection assay using
probe A, shown in Fig. 1A, was performed to determine the relative levels of the
2.8- and 3.5-kb mRNAs in RNA from C15, IB4, a pool of NPC biopsy samples
(NPC), and the BL cell line Akata (AKA) (30). Louckes (LKE) is an EBV-
negative LCL. Fully protected probe (346 nt), representing the 3.5-kb LMP1
mRNA, was detected in C15 and the NPC biopsy pool at approximately equal
levels relative to the partially protected fragments of 290 to 295 nt, which
represent the 2.8-kb mRNA. Fully protected fragments were detected at greatly
reduced levels in IB4 and Akata. The following approximate ratios of 3.5-kb
mRNA to 2.8-kb mRNA were determined by densitometry of the autoradio-
gram: C15, 1:1; IB4, 1:9; NPC, 1:1; Akata, 1:10.
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and tumorigenicity in nude mice (3, 22, 31). In B cells, LMP1
expression induces the NF-kB transcription factor and trans-
activates a number of other genes, including B-cell activation
markers and the A20 and bcl-2 oncogenes, all of which are
associated with a transformed cell phenotype (17, 18, 23, 32).
LMP1 expression is also likely to be an important component
of epithelial cell malignancies such as NPC. This study dem-
onstrates that the transcription of LMP1 in NPC is distinct
from that in LCLs, both in terms of promoter usage and reg-
ulation, and has identified a possible regulatory mechanism
controlling expression of LMP1 in NPC.
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